Fig. 1: The influence of priming vaccination on the antigen-specific IgG1/IgG2a antibody responses and antibody cross-reactivity. | Nature Communications

Fig. 1: The influence of priming vaccination on the antigen-specific IgG1/IgG2a antibody responses and antibody cross-reactivity.

From: Enhancing cross-protection against influenza by heterologous sequential immunization with mRNA LNP and protein nanoparticle vaccines

Fig. 1

a Schematic diagram of immunization and sera collection. Mice were immunized twice with either IM (mRNA) or IN (PHC) vaccines at an interval of 4 weeks. Sera were collected 3 weeks post-prime for one-dose IN (PHC) and IM (mRNA) groups or 3 weeks post-boost for two-dose groups. b, c Comparison of the antigen-specific total IgG, IgG subtype (IgG1 and IgG2a) levels, and IgG1/IgG2a ratio in IN (PHC), IM (mRNA)+IN (PHC), and IN (PHC)+IN (PHC) groups. d, e Comparison of the antigen-specific total IgG, IgG subtype (IgG1 and IgG2a), and IgG1/IgG2a ratio in IM (mRNA), IN (PHC)+IM (mRNA), and IM (mRNA)+IM (mRNA) groups. f, g Cross-reactive IgG antibody levels against heterologous Phi and heterosubtypic rSH viruses. IM intramuscular, IN intranasal, PHC polyethyleneimine-HA/CpG, Phi A/Philippines/2/1982 (H3N2), rSH reassortant A/Shanghai/2/2013 (H7N9). Group definitions: Single-dose IN (PHC), orange with patterns, Single-dose IM (mRNA), green with patterns, IM (mRNA)+IN (PHC), blue; IN (PHC)+IN (PHC), orange; IN (PHC)+IM (mRNA), purple; IM (mRNA)+IM (mRNA), green. Data are presented as mean ± SEM (n = 5). Statistical significance was analyzed by one-way ANOVA followed by Turkey’s multiple comparison tests. Source data are provided as a Source Data file.

Back to article page